Key Financial Figures (Q1 FY27 vs Q1 FY26)

  • Revenue: ₹798 crore (vs ₹670 crore), growth of 19.1% YoY
  • Material consumed: ₹152 crore (vs ₹129 crore)
  • Employee benefit Expenses: ₹133 crore (vs ₹124 crore)
  • Fees to collection centres: ₹116 crore (vs ₹96 crore)
  • Other Expenses: ₹150 crore (vs ₹129 crore)
  • EBITDA: ₹247 crore (vs ₹192 crore), growth of 28.7% YoY
  • EBITDA Margins: 31.0% (vs 28.7%)
  • Other Income: ₹32 crore (vs ₹28 crore)
  • Depreciation Cost: ₹44 crore (vs ₹35 crore)
  • Finance Cost: ₹6 crore (vs ₹5 crore)
  • PBT: ₹229 crore (vs ₹181 crore), growth of 26.3% YoY
  • PBT Margins: 28.7% (vs 27.0%)
  • Income Tax: ₹58 crore (vs ₹47 crore)
  • PAT: ₹170 crore (vs ₹134 crore), growth of 27.2% YoY
  • PAT Margins: 21.4% (vs 20.0%)
  • EPS (Basic): ₹10.1 (vs ₹7.9), growth of 27.8% YoY

Operational Highlights

  • Achieved highest quarterly revenue growth in last 4 years
  • Volume-led revenue growth: 10.7% YoY sample volume growth and 8.2% patient volume growth
  • Growth driven by underlying organic business strength
  • Increase in operating margin due to economies of scale and cost efficiencies
  • ROCE* improved to 58% (vs 44% in FY26)

Management Commentary

(Hony.) Brig. Dr. Arvind Lal, Executive Chairman:

  • Indian diagnostics industry remains in structural growth phase driven by rising burden of lifestyle diseases, growing health awareness, and rising disposable incomes
  • Launched rural outreach program now active in 7 states (UP, Bihar, MP, Rajasthan, Jharkhand, Orissa, West Bengal)
  • Tested more than 110,000 patients in rural areas in Q1 FY27
  • Company well positioned to benefit from industry shift through investment in scientific leadership, R&D, digital infrastructure and service standards

Mr. Ved Goel, Group CFO & CEO – International Business:

  • Strong performance driven by healthy volume growth and improved test and geography mix
  • Disciplined execution enabled sustained strong profitability while reinvesting in business for long-term growth
  • Healthy cash position provides strategic flexibility and ability to pursue inorganic growth opportunities
  • Confident in outlook and ability to deliver sustainable and profitable growth

Mr. Shankha Banerjee, Chief Executive Officer:

  • Entered new fiscal year with strong operational momentum sustaining resilient growth trajectory from FY26
  • Distinctiveness in high-complexity portfolio strengthened with launch of 4 "First in India" tests
  • Strengthening academic partnerships and R&D efforts to retain pre-eminent position in advanced diagnostics
  • Growth strategy focused on Scientific Leadership, enhanced Patient Experience and Operational Excellence

Strategic Initiatives

  • GraminFit: Scalable rural preventive healthcare program expanded to 7 states serving over 100,000 patients in Q1 FY27
  • Digital Transformation: Implementing GenAI for customer interactions (90% queries handled by bots), unified communication engine, AI-powered SEO, smart culture reporting
  • Cyber Security: Enhanced capabilities including Extended Detection & Response, SASE, EDR, Cloud Native SIEM/SOAR, Security Operations Center monitoring 24x7
  • Quality Standards: CAP Proficiency Testing Score at 98.1% for National Reference Lab, EQAS Performance Testing Score at 98.2% for Satellite Labs, CAP accreditation for 2 labs, NABL accreditation for 53 labs
  • Patent: Granted for invention related to REAL TIME QUALITY CONTROL MONITORING for 20 years

Corporate Overview

  • Integrated nationwide network: 312 clinical labs (including 4 Reference Labs), 7,727 Patient Service Centers, 13,935 Pick-up Points
  • Service catalog: 525 test panels, 3,130 pathology tests, 1,173 radiology and cardiology tests as on March 31, 2026
  • In FY26: Processed approximately 94.5 million samples from 30.3 million patients
  • Corporate Identification No: L74899DL1995PLC065388